Prevalence of drug-drug interactions in oncology patients enrolled on National Clinical Trials Network oncology clinical trials

被引：0
|
作者：
Lauren A. Marcath
Taylor D. Coe
Emily K. Hoylman
Bruce G. Redman
Daniel L. Hertz
机构：
[1] University of Michigan,Department of Clinical Pharmacy
[2] College of Pharmacy,Department of Internal Medicine – Hematology/Oncology
[3] University of Michigan,undefined
[4] Michigan Medicine,undefined
来源：
BMC Cancer | / 18卷
关键词：
Oncology clinical trial drug interaction;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [11] Fasting conditions in clinical oncology trials and drug labelling
    Yu, Guo
    Li, Guo-Fu
    Wang, Da-Xin
    Wang, Jingcheng
    Zhou, Hong-Hao
    LANCET ONCOLOGY, 2017, 18 (09): : E506 - E506
  • [12] Navigating Oncology Clinical Trials: From Drug Development to
    Bourgeois, John
    Goodman, Monica S.
    Braga, Catherine
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2025, 29 (01) : 91 - 95
  • [13] Prevalence and Significance of Potential Pharmacokinetic Drug-Drug Interactions Among Patients with Lung Cancer: Implications for Clinical Trials
    Rashdan, Sawsan
    Yang, Hui
    Le, Tri
    Selby, Christopher
    Gerber, David E.
    Alvarez, Carlos A.
    CLINICAL DRUG INVESTIGATION, 2021, 41 (02) : 161 - 167
  • [14] Drug-drug interactions in subjects enrolled in SWOG trials of oral chemotherapy
    Marcath, Lauren A.
    Finley, Colin M.
    Wong, Siu Fun
    Hertz, Daniel L.
    BMC CANCER, 2021, 21 (01)
  • [15] Drug-drug interactions in subjects enrolled in SWOG trials of oral chemotherapy
    Lauren A. Marcath
    Colin M. Finley
    Siu Fun Wong
    Daniel L. Hertz
    BMC Cancer, 21
  • [16] Fasting conditions in clinical oncology trials and drug labelling Reply
    Lubberman, Floor J. E.
    Burger, David
    van Erp, Nielka P.
    LANCET ONCOLOGY, 2017, 18 (09): : E507 - E507
  • [17] Drug Shortages Strain Cancer Treatment and Oncology Clinical Trials
    Boughton, Barbara
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2011, 4 (06): : 397 - 397
  • [18] Polypharmacy in hematology and oncology patients and the resulting prevalence of potential drug-drug interactions (DDI)
    Metzke, B.
    Fink, G.
    Hieke, S.
    Jung, M.
    Hug, M. J.
    Engelhardt, M.
    ONKOLOGIE, 2012, 35 : 76 - 76
  • [19] Patients in Clinical Trials are Sub-Optimally Protected for Drug-Drug Interactions: A Call for Action
    Burger, David
    de Jong, Loek
    van Dijk, Daphne
    Knibbe, Catherijne A. J.
    ter Heine, Rob
    Smolders, Elise
    Pirmohamed, Munir
    JOURNAL OF CLINICAL PHARMACOLOGY, 2024,
  • [20] Clinical trials in oncology
    Matos, Erika
    ONKOLOGIJA, 2018, 22 (01) : 38 - 41
12345